RNA (Atrium Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 02, 2026)

Atrium Therapeutics  (NAS:RNA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Atrium Therapeutics 5-Year Yield-on-Cost % Related Terms

RNA vs CNTN, QTTB, TARA: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Atrium Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's 5-Year Yield-on-Cost % falls into.

Atrium Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Atrium Therapeutics is calculated as

Atrium Therapeutics Business Description